Eton Pharmaceuticals Inc. has announced the licensing of U.S. marketing rights to a product candidate intended for the treatment of an ultra-rare disease affecting fewer than 100 patients in the United States. The company plans to launch this product, pending FDA approval, in mid-2026, positioning it as the first and only generic alternative for the condition. Eton aims to integrate this asset into its existing commercial infrastructure and expand its portfolio of ultra-rare disease products. The company also intends to provide patient support through its Eton Cares program and continues to pursue additional high-value, ultra-rare disease product opportunities, with further product launches targeted for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646429-en) on February 02, 2026, and is solely responsible for the information contained therein.